ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1801

Serum Cathepsin-S Concentration Is Not Related to Arterial Calcification Severity Among Hemodialysis Patients

Session Information

Category: Hypertension and CVD

  • 1402 Hypertension and CVD: Clinical, Outcomes, and Trials

Authors

  • Ma, Hao-Wei, Taipei Veterans General Hospital, Taipei, Taiwan
  • Lin, Chih-Ching, Taipei Veterans General Hospital, Taipei, Taiwan
  • Li, Szu-Yuan, Taipei Veterans General Hospital, Taipei, Taiwan
Background

Vascular calcification is prevalent among hemodialysis patients and is strongly correlated to their cardiovascular and total mortality. Cathepsin S, a lysosomal cysteine protease that is elevated in CKD patients, has shown its critical role of vascular calcification in cell culture experiments and in uremic animal model. To validate the relationship of Cathepsin S and vascular calcification in clinical practice, we conducted the current cross sectional study.

Methods

88 patients on maintenance hemodialysis were enrolled and their serum Cathepsin S and its natural inhibitor Cystatin C were measured. Severity of vascular calcification was semi-quantified by aortic arch calcification (AAC) score on chest X-rays. Patients were divided into groups according to their AAC score, and the serum Cathepsin S level, Cathepsin S / Cystatin C ratio and other factors were compared between groups.

Results

There was no significant difference in the level of Cathepsin S (p=0.778) or Cathepsin S to Cystatin C ratio (p=0.417) between patients with different aortic arch calcification score. Only age was associated with the severity of AAC score (p=0.014). Increasing serum triglyceride level is significantly associated with higher serum Cathepsin S level (Pearson Correlation p=0.001, R square=0.133).

Conclusion

Despite a pre-clinical study supporting the role of Cathepsin S in the development of vascular calcification under uremic and phosphate-rich conditions, serum Cathepsin S was not found to be associated with vascular calcification severity among hemodialysis patients in this study. Serum triglyceride is the strongest predicting factor for higher Cathepsin S levels in these patients. Further study is needed to confirm these findings using a different grading system.

Mean age and serum Cathepsin S with 95% confidence interval between groups of patients, categorized by their Aortic arch calcification (AAC) grade.